Literature DB >> 12490732

Optimization of trans-splicing ribozyme efficiency and specificity by in vivo genetic selection.

Brian G Ayre1, Uwe Köhler, Robert Turgeon, Jim Haseloff.   

Abstract

Trans-splicing ribozymes are RNA-based catalysts capable of splicing RNA sequences from one transcript specifically into a separate target transcript. In doing so, a chimeric mRNA can be produced, and new gene activities triggered in living cells dependent on the presence of the target mRNA. Based on this ability of trans-splicing ribozymes to deliver new gene activities, a simple and versatile plating assay was developed in Saccharomyces cerevisiae for assessing and optimizing constructs in vivo. Trans-splicing ribozymes were used to splice sequences encoding a GAL4-derived transcription activator into a target transcript from a prevalent viral pathogen. The transcription activator translated from this new mRNA in turn triggered the expression of genes under the regulatory control of GAL4 upstream-activating sequences. Two of the activated genes complemented metabolic deficiencies in the host strain, and allowed growth on selective media. A simple genetic assay based on phenotypic conversion from auxotrophy to prototrophy was established to select efficient and specific trans-splicing ribozymes from a ribozyme library. This simple assay may prove valuable for selecting optimal target sites for therapeutic agents such as ribozymes, antisense RNA and antisense oligodeoxyribonucleotides, and for optimizing the design of the therapeutic agents themselves, in higher eukaryotes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490732      PMCID: PMC140090          DOI: 10.1093/nar/gnf141

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  28 in total

1.  Antisense RNA regulation in prokaryotes: rapid RNA/RNA interaction facilitated by a general U-turn loop structure.

Authors:  T Franch; M Petersen; E G Wagner; J P Jacobsen; K Gerdes
Journal:  J Mol Biol       Date:  1999-12-17       Impact factor: 5.469

2.  Design of highly specific cytotoxins by using trans-splicing ribozymes.

Authors:  B G Ayre; U Köhler; H M Goodman; J Haseloff
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  GAL4-VP16 is an unusually potent transcriptional activator.

Authors:  I Sadowski; J Ma; S Triezenberg; M Ptashne
Journal:  Nature       Date:  1988-10-06       Impact factor: 49.962

4.  Simple RNA enzymes with new and highly specific endoribonuclease activities.

Authors:  J Haseloff; W L Gerlach
Journal:  Nature       Date:  1988-08-18       Impact factor: 49.962

5.  RNA structure, not sequence, determines the 5' splice-site specificity of a group I intron.

Authors:  J A Doudna; B P Cormack; J W Szostak
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

6.  The conserved U.G pair in the 5' splice site duplex of a group I intron is required in the first but not the second step of self-splicing.

Authors:  E T Barfod; T R Cech
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

7.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

8.  A family of yeast expression vectors containing the phage f1 intergenic region.

Authors:  T Vernet; D Dignard; D Y Thomas
Journal:  Gene       Date:  1987       Impact factor: 3.688

9.  Catalytic activity is retained in the Tetrahymena group I intron despite removal of the large extension of element P5.

Authors:  G F Joyce; G van der Horst; T Inoue
Journal:  Nucleic Acids Res       Date:  1989-10-11       Impact factor: 16.971

10.  Alteration of substrate specificity for the endoribonucleolytic cleavage of RNA by the Tetrahymena ribozyme.

Authors:  F L Murphy; T R Cech
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more
  9 in total

1.  An in vivo selection method to optimize trans-splicing ribozymes.

Authors:  Karen E Olson; Ulrich F Müller
Journal:  RNA       Date:  2012-01-24       Impact factor: 4.942

2.  Low selection pressure aids the evolution of cooperative ribozyme mutations in cells.

Authors:  Zhaleh N Amini; Ulrich F Müller
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

3.  Direct selection for ribozyme cleavage activity in cells.

Authors:  Xi Chen; Lisa Denison; Matthew Levy; Andrew D Ellington
Journal:  RNA       Date:  2009-09-23       Impact factor: 4.942

4.  Engineering a family of synthetic splicing ribozymes.

Authors:  Austin J Che; Thomas F Knight
Journal:  Nucleic Acids Res       Date:  2010-03-18       Impact factor: 16.971

5.  Functional characterization of the Arabidopsis AtSUC2 Sucrose/H+ symporter by tissue-specific complementation reveals an essential role in phloem loading but not in long-distance transport.

Authors:  Avinash C Srivastava; Savita Ganesan; Ihab O Ismail; Brian G Ayre
Journal:  Plant Physiol       Date:  2008-07-23       Impact factor: 8.340

6.  Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; Tiffany A Kolniak; Lowell G Sheflin; R Thomas Taggart; Heba E Abdelmaksoud
Journal:  J Ophthalmol       Date:  2011-06-30       Impact factor: 1.909

Review 7.  Design and Experimental Evolution of trans-Splicing Group I Intron Ribozymes.

Authors:  Ulrich F Müller
Journal:  Molecules       Date:  2017-01-02       Impact factor: 4.411

8.  In vivo evolution of a catalytic RNA couples trans-splicing to translation.

Authors:  Karen E Olson; Gregory F Dolan; Ulrich F Müller
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

9.  Modifying the Replication of Geminiviral Vectors Reduces Cell Death and Enhances Expression of Biopharmaceutical Proteins in Nicotiana benthamiana Leaves.

Authors:  Andrew G Diamos; Hugh S Mason
Journal:  Front Plant Sci       Date:  2019-01-09       Impact factor: 5.753

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.